ADE as Induction Therapy Results in Treatment of Children with Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries ()
ABSTRACT
Background: In Mexico, AML survival is referred in 30%. Our aim was to
evaluate results with ADE protocol as induction treatment in children with
non-M3 AML in a public Mexican institution. Method: We included patients with
AML in a single institution between 2005 and 2013. All non-M3-AML patients
received ADE as induction therapy (cytarabine 100 mg/m2 in continuous
infusion from day 1 to 7, daunorrubicin 30 mg/m2 days 1, 3, 5 and
etoposide 100 mg/m2 over days 1 to 5). Patients received antibiotic
prophylaxis and strict scheduled appointments to assure adherence and prevent
avoidable emergencies. Main Results: Eighteen patients were included. Median
age was 106 months. One patient died at diagnosis so 17 were eligible for
induction results analysis; eleven needed two cycles and six patients three.
Remission rate was 100%. Analyzing non-M3 patients overall survival was 80.2%
at 100 months. No fatal complications were observed. Stratifying by number of cycles
we observe that patients receiving one ADE cycle had a 0% overall survival at
short follow up, with 2 ADE cycles 80% at 100 months and with 3 cycles 100% at
60 months. Conclusion: ADE induction therapy showed improved results in overall
survival compared with other standard regimens. Following the protocol we
obtained 100% remission. This is an important achievement in our population.
Our focus must be to ameliorate maintenance final results. These results should
be reproduced in other hospitals in Mexico and other countries.
Share and Cite:
Zapata-Tarrés, M. , Cárdenas-Cardós, R. , Velasco-Hidalgo, L. , Pérez-García, M. , Olaya-Vargas, A. , Cárdenas-Pedraza, D. and Rivera-Luna, R. (2016) ADE as Induction Therapy Results in Treatment of Children with Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries.
Journal of Cancer Therapy,
7, 197-202. doi:
10.4236/jct.2016.73020.
Cited by
No relevant information.